These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9017347)

  • 21. The cost of treating type 2 diabetes (CODEIRE).
    Nolan JJ; O'Halloran D; McKenna TJ; Firth R; Redmond S
    Ir Med J; 2006; 99(10):307-10. PubMed ID: 17274175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmaco-economics of type 2 diabetes].
    Scheen AJ; Lefèbvre PJ
    Rev Med Liege; 1998 May; 53(5):285-9. PubMed ID: 9689884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care.
    Killilea T
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S441-9. PubMed ID: 12408407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Data nail down the astounding cost of diabetes-related care.
    Capitation Rates Data; 2001 Apr; 6(4):42-5. PubMed ID: 11330006
    [No Abstract]   [Full Text] [Related]  

  • 25. [The costs of diabetes mellitus and its complications in Germany].
    Hauner H
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S240-2. PubMed ID: 17139578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vascular wall and diabetes mellitus: what complications and why?].
    Marre M
    Therapie; 1997; 52(5):371-4. PubMed ID: 9501559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mechanisms of development of diabetic macroangiopathy].
    Saltykov BB
    Arkh Patol; 2001; 63(2):21-6. PubMed ID: 11392087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The economic burden of insulin resistance.
    Turtle JR
    Int J Clin Pract Suppl; 2000 Oct; (113):23-8. PubMed ID: 11965827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for asymptomatic coronary artery disease in patients with type 2 diabetes.
    Vinik AI; Maser RE
    JAMA; 2009 Aug; 302(7):735-6; author reply 736-7. PubMed ID: 19690298
    [No Abstract]   [Full Text] [Related]  

  • 30. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.
    Sullivan MD; Anderson RT; Aron D; Atkinson HH; Bastien A; Chen GJ; Feeney P; Gafni A; Hwang W; Katz LA; Narayan KM; Nwachuku C; O'Connor PJ; Zhang P;
    Am J Cardiol; 2007 Jun; 99(12A):90i-102i. PubMed ID: 17599429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A cost of illness study of diabetes mellitus].
    von Ferber L; Köster I; Hauner H
    Gesundheitswesen; 1997 Jan; 59(1):17-22. PubMed ID: 9138642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevention and early therapy play too minor a role in our health care system].
    Rothe HJ
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():22-3. PubMed ID: 14694840
    [No Abstract]   [Full Text] [Related]  

  • 33. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study.
    Liebl A; Breitscheidel L; Nicolay C; Happich M
    Curr Med Res Opin; 2008 Aug; 24(8):2349-58. PubMed ID: 18606055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for asymptomatic coronary artery disease in patients with type 2 diabetes.
    Chikamori T
    JAMA; 2009 Aug; 302(7):735; author reply 736-7. PubMed ID: 19690299
    [No Abstract]   [Full Text] [Related]  

  • 35. [Use of angiotensin I converting enzyme inhibitors --essential progress in treatment of hypertension and late complications in patients with non-insulin-dependent diabetes mellitus].
    Czekalski S
    Pol Tyg Lek; 1993 Apr; 48 Suppl 1():33-4. PubMed ID: 8516204
    [No Abstract]   [Full Text] [Related]  

  • 36. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.
    O'Brien JA; Patrick AR; Caro J
    Clin Ther; 2003 Mar; 25(3):1017-38. PubMed ID: 12852716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunomorphological characteristics of microangiopathy in non-insulin-dependent diabetes mellitus].
    Saltykov BB; Velikov VK; Shubina OI
    Sov Med; 1986; (4):20-4. PubMed ID: 2940702
    [No Abstract]   [Full Text] [Related]  

  • 38. Screening for asymptomatic coronary artery disease in patients with type 2 diabetes.
    Vidovich MI
    JAMA; 2009 Aug; 302(7):736; author reply 736-7. PubMed ID: 19690300
    [No Abstract]   [Full Text] [Related]  

  • 39. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronary artery disease and cerebrovascular disease prevention in diabetes mellitus: early identification and aggressive modification of risk factors.
    Hennessey JV; Westrick E
    Med Health R I; 1998 Nov; 81(11):350-2. PubMed ID: 15580789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.